Neurological Biomarkers Market, By Biomarker Type (Artificial Tears, Imaging Biomarkers, Metabolomics Biomarkers, Proteomic Biomarkers, Genomics Biomarkers), By Application (Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Autism Spectrum Disorders, Others), By End User (Hospital Laboratories, Clinical Diagnostic Centers, Research Organizations, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Jun 2024

Code : CMI4586

Pages :174

Formats :

Excel and PDF

Industry : Biotechnology

Market Concentration and Competitive Landscape

Neurological Biomarkers Market Concentration By Players

Close-monitor your Competitor's Move, Request sample copy

Advances in Proteomic and Genomic Technologies

Significant technological advancements in the field of proteomics and genomics have facilitated the discovery and validation of novel neurological biomarkers. Techniques such as quantitative proteomics, mass spectrometry imaging, next generation sequencing, bioinformatics are enabling researchers to identify potential protein, genetic and metabolic biomarkers associated with different neurological conditions. For instance, technologies have helped to identify cerebrospinal fluid and blood biomarkers for Alzheimer's disease pathology as well as potential genetic variants associated with increased Parkinson's disease risk. The advancements in imaging technologies have enabled monitoring of structural and functional changes in the brain through biomarkers. Novel technologies are also aiding the development of multi-analyte biomarker panels and disease subtyping through integrated omics analysis. This is expected to revolutionize disease diagnosis, monitoring and facilitate personalized treatment approaches. Continued investments in proteomic and genomic research globally are likely to significantly contribute towards the ongoing identification and clinical adoption of novel reliable neurological biomarkers.

Key Players Insights